AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study

AstraZeneca Plc AZN reported topline data from the DESTINY-Breast02 phase 3 trial of Enhertu (trastuzumab deruxtecan).
The trial evaluated Enhertu versus (trastuzumab/capecitabine or lapatinib/capecitabine) in HER2 positive unresectable and/or metastatic breast cancer previously treated with T-DM1.
The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial also met the key secondary endpoint of improved overall survival.
Related: Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation.
ENnhertu is a HER2-directed antibody-drug conjugate (ADC) jointly developed and commercialized by Daiichi Sankyo DSKNY and AstraZeneca.
The safety profile of Enhertu was consistent with previous phase 3 clinical trials, with no new safety concerns identified. Interstitial lung disease (ILD) rates and severity were consistent observed in other metastatic breast cancer trials of Enhertu.
The data will be presented at an upcoming medical meeting.
Price Action: AZN shares are up 0.44% at $66.93 during the premarket session on the last check Monday.